TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of N-acetylcysteine on Muscle Fatigue in ESRD
Brief Summary: The purposes of the study are to determine whether oxidative stress causes the muscle of dialysis patients to tire more quickly than muscle of people without kidney disease and to determine whether treatment with N-acetylcysteine, an antioxidant, can improve muscle endurance.


Options:
A: Arm Label: N-acetylcysteine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: N-acetylcysteine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: N-acetylcysteine; Assigned to Arm(s): N-acetylcysteine | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: No exercise; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Treatment | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise training | Intervention Type: OTHER; Name: Usual Treatment; Assigned to Arm(s): No exercise
D: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria
Brief Summary: The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax malaria.


Options:
A: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
B: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)
C: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
D: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria
Brief Summary: The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax malaria.


Options:
A: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate
B: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
C: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group
D: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria
Brief Summary: The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax malaria.


Options:
A: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
B: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
C: Arm Label: Artekin; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin + Piperaquine (Artekin) | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: artesunate-sulphadoxin/pyrimethamine, chloroquine | Intervention Type: DRUG; Name: Dihydroartemisinin + Piperaquine (Artekin); Assigned to Arm(s): Artekin | Intervention Type: DRUG; Name: artesunate-sulphadoxin/pyrimethamine, chloroquine; Assigned to Arm(s): Standard treatment
D: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria
Brief Summary: The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax malaria.


Options:
A: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
B: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
C: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)
D: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Assess Whether Type 1 Diabetic Patients Treated With M D I and in Poor Metabolic Control Can Improve Using the Paradigm® Real Time System Compared to Self-Monitoring Blood Glucose and Continuous Subcutaneous Insulin Infusion
Brief Summary: In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive and display CGM data from a separate subcutaneous glucose sensor, or conventional CSII, and compared glycemic outcomes after 6 months.


Options:
A: Arm Label: Conventional insulin pump therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Minimed Paradigm 512/712 Insulin pump | Arm Label: Minimed paradigm Real Time Sytem; Type: EXPERIMENTAL; Interventions: Device: Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed paradigm Real Time Sytem; Assigned to Arm(s): Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed Paradigm 512/712 Insulin pump; Assigned to Arm(s): Conventional insulin pump therapy
B: Arm Label: Open; Type: EXPERIMENTAL; Interventions: Device: Real-Time Continuous Glucose monitoring System (RT-CGMS) | Arm Label: Blind; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Real-Time Continuous Glucose monitoring System (RT-CGMS); Assigned to Arm(s): Open
C: Arm Label: 722 sensor augmented pump; Type: EXPERIMENTAL; Interventions: Device: MiniMed Paradigm REAL-Time System | Arm Label: Multiple Daily Injections (MDI); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MiniMed Paradigm REAL-Time System; Assigned to Arm(s): 722 sensor augmented pump
D: Arm Label: Standard intensive glucose monitoring; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continuous Glucose Monitoring (CGM); Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous glucose monitor | Intervention Type: DEVICE; Name: Continuous glucose monitor; Assigned to Arm(s): Continuous Glucose Monitoring (CGM)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa
Brief Summary: This phase IIb, two-arm, double-blinded, randomised, placebo controlled trial comparing 1% Tenofovir gel with a placebo gel is an expanded safety and effectiveness trial involving 900 young women at risk of sexually transmitted HIV infection. Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study gel within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. All participants will receive HIV risk reduction counselling, condoms, and syndromic treatment of sexually transmitted infections, if required.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Universal HEC placebo) | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo (Universal HEC placebo); Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Carraguard (PC-515); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BufferGel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: PRO 2000/5 Gel | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: BufferGel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PRO 2000/5 Gel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acidform Lubricant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: HEC gel | Intervention Type: DRUG; Name: Acidform Lubricant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: HEC gel; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III: The Study of Acid Reflux in Children With Asthma
Brief Summary: Many individuals with asthma also experience gastroesophageal reflux disease (GERD), a condition in which excess stomach acid flows backwards into the esophagus. This study will evaluate the effectiveness of lansoprazole, a medication commonly used to treat GERD in improving asthma control and reducing symptoms in children with poorly controlled asthma.


Options:
A: Arm Label: Tiotropium Respimat (low dose); Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Respimat | Arm Label: Tiotropium Respimat (high dose); Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Respimat | Arm Label: Placebo Respimat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Respimat | Intervention Type: DRUG; Name: Tiotropium Respimat; Assigned to Arm(s): Tiotropium Respimat (high dose) | Intervention Type: DRUG; Name: Placebo Respimat; Assigned to Arm(s): Placebo Respimat | Intervention Type: DRUG; Name: Tiotropium Respimat; Assigned to Arm(s): Tiotropium Respimat (low dose)
B: Arm Label: Lansoprazole; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Lansoprazole; Assigned to Arm(s): Lansoprazole | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Esomeprazole 40 mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Esomeprazole 40 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 40 mg twice daily | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 40 mg once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo for esomeprazoe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo proton pump inhibitor | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo proton pump inhibitor; Assigned to Arm(s): Placebo for esomeprazoe

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg.
Brief Summary: European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)


Options:
A: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg
B: Arm Label: 1; Type: OTHER; Interventions: Drug: ezetimibe (+) simvastatin, Drug: Comparator: atorvastatin calcium, Drug: Comparator: Placebo (unspecified) | Arm Label: 2; Type: OTHER; Interventions: Drug: ezetimibe (+) simvastatin, Drug: Comparator: atorvastatin calcium, Drug: Comparator: Placebo (unspecified) | Arm Label: 3; Type: OTHER; Interventions: Drug: ezetimibe (+) simvastatin, Drug: Comparator: atorvastatin calcium, Drug: Comparator: Placebo (unspecified) | Arm Label: 4; Type: OTHER; Interventions: Drug: ezetimibe (+) simvastatin, Drug: Comparator: atorvastatin calcium, Drug: Comparator: Placebo (unspecified) | Arm Label: 5; Type: OTHER; Interventions: Drug: ezetimibe (+) simvastatin, Drug: Comparator: atorvastatin calcium, Drug: Comparator: Placebo (unspecified) | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): 1, 2, 3, 4, 5 | Intervention Type: DRUG; Name: Comparator: atorvastatin calcium; Assigned to Arm(s): 1, 2, 3, 4, 5 | Intervention Type: DRUG; Name: Comparator: Placebo (unspecified); Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Atorvastatin Placebo; Assigned to Arm(s): Arm 2
D: Intervention Type: DRUG; Name: Atorvastatin (Lipitor); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Mosquito Coils to Control Malaria in China
Brief Summary: Although mosquito coils are widely used, there is no robust evidence that their use can provide clinical reduction in malaria. This study will randomise 4 groups of 400 houses, each with 5 people, in rural China and monitor cases of malaria in each group each month for 6 months. The treatment groups will include Coils, Treated bed nets, Coils plus treated bed nets, or no treatment (control). All cases detected will be given prompt appropriate treatment.


Options:
A: Arm Label: Mosquito repellent and LLINs group vs. LLINs group only; Type: EXPERIMENTAL; Interventions: Other: Mosquito repellent | Intervention Type: OTHER; Name: Mosquito repellent; Assigned to Arm(s): Mosquito repellent and LLINs group vs. LLINs group only
B: Arm Label: Topical Repellent & LLIN; Type: EXPERIMENTAL; Interventions: Other: Mosquito topical repellent | Arm Label: Long Lasting Insecticidal Nets; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mosquito topical repellent; Assigned to Arm(s): Topical Repellent & LLIN
C: Intervention Type: DEVICE; Name: Insect Repellent plus Insecticide Treated Net; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: LLIN | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Intervention Type: DEVICE; Name: mosquito coils; Assigned to Arm(s): 3, 4 | Intervention Type: DEVICE; Name: LLIN; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Transcervical Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction
Brief Summary: The purpose of this study is to compare the efficacy of a transcervical Foley catheter with and without extra-amniotic saline infusion (EASI) for priming the cervix for labor.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Induction of labor with foley balloon - 60cc of saline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Induction of labor with foley balloon with 30cc | Intervention Type: PROCEDURE; Name: Induction of labor with foley balloon - 60cc of saline; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Induction of labor with foley balloon with 30cc; Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Transcervical Foley Catheter; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Transcervical Foley Catheter with an EASI; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: low dose oxytocin; Assigned to Arm(s): N/A
D: Arm Label: Cook Cervical balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: Cook cervical balloon | Arm Label: Prostin E2 Vaginal suppository; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prostin E2 Vaginal Suppository | Intervention Type: DEVICE; Name: Cook cervical balloon; Assigned to Arm(s): Cook Cervical balloon | Intervention Type: DRUG; Name: Prostin E2 Vaginal Suppository; Assigned to Arm(s): Prostin E2 Vaginal suppository

Answer: B